Health Tech Capitol | Alumnus’s startup seeks more precise screening for prostate cancer
15730
post-template-default,single,single-post,postid-15730,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Alumnus’s startup seeks more precise screening for prostate cancer

Alumnus’s startup seeks more precise screening for prostate cancer

Last fall, while discussing inventions awaiting commercialization at the Wisconsin Alumni Research Foundation, Tobias Zutz stumbled across one with an uncanny match to his resume. Zutz was an early employee at Exact Sciences, a Madison firm that has developed a screening test for colon cancer based on colon cells excreted in the stool.

The experience made him appreciate the benefits of novel ways to obtain samples from cancer-prone tissues.

The discovery in question described a new way to identify cancerous prostate cells. The inventor, David Jarrard, a professor of urology at the UW–Madison School of Medicine and Public Health, had found eight telltale molecular structures on genes during a decades-long quest to detect prostate cancer in men while it was still treatable.

Read more at UW-Madison News

No Comments

Sorry, the comment form is closed at this time.